KARO

Roche Pharma (Switzerland):
Guard-C is a global observational cohort study on the prediction of unwanted adverse effects in individuals infected with chronic hepatitis C.


Ncore is a four-month treatment course for patients with particular strains of chronic hepatitis C who have low virus levels before starting treatment, and who show a rapid virological response by clearing the virus from the blood within the first 4 weeks of treatment. This shorter treatment duration provides patients with the full benefits of therapy while reducing unnecessary drug exposure. The logo incorporates the time frames of treatment, and graphically represents the patient’s response of moving ahead.




Black and white logo variation with full study name.




Free-S-Be is a global interventional study on hepatitis B.




Prophesys is a large multinational observational study, identifying factors that influence hepatitis C patients’ response to treatment. The study examines whether it is possible to predict if a patient will achieve a cure based on his or her response to treatment at weeks 2, 4 or 12. The logo includes a graphic translation of these time intervals relating to dosage of the medication.




Sketches with various graphic translations. The lines represent a combination of time, dosage and the circulatory system.



Xeloda is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. The patient’s therapy diary is used to monitor treatment progress and possible side-effects. There is a dosage register on the right-hand pages and space for personal notes on the left. The spiral binding is useful for patients requiring privacy when discussing dosage scheduling with their medical advisor, as the notes can be flipped back and concealed.




roche.ch